It’s easy to get excited about breakthrough drugs, but this chat reminds us that real-world factors—like international disputes or manufacturing hiccups—can throw a wrench into progress. If you care about where those pricey new treatments actually come from (or why they might get delayed), this conversation’s worth a listen.

<p>In this episode of Wall Street Week, we talk to a longtime diplomat and the CEO of Johnson &amp; Johnson</p>

A new episode of Wall Street Week dives into the collision of two big forces: the booming pharmaceutical industry (dubbed a "golden era" for drug innovation) and the shaky state of global politics. Guests include a seasoned diplomat and Johnson & Johnson’s CEO, likely unpacking how things like trade tensions or supply chain snags could shake up access to cutting-edge meds.